Biotechnology

BioInvent to Present Pipeline Progress on BI-1910 and BT-001 at ESMO

July 22, 2024 2:20 AM

LUND, SWEDEN / ACCESSWIRE / July 22, 2024 / BioInvent International (STO:BINV) Two posters to be presented on early clinical projects from BioInvent's robust pipeline totaling six clinical programs: Progress with the Phase 1 trial studying BI-1910 as single agent in solid tumors Initial clinical data from the BT-001 Phase 1 study evaluating the candidate both as single agent and in combination with KEYTRUDA® (pembrolizumab) in patients with...

Read more

Biomind Labs To Redefine Obesity Treatment With Its New BMND06 Candidate Targeting Neurological Pathways

July 18, 2024 8:30 AM

Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), a leading biotech company dedicated to developing the next-generation of pharmaceuticals targeting the root causes of neurological disorders, announced the decision to advance a new Phase II clinical trial. This decision follows new and unexpected findings from a pre-clinical study of its proprietary compound 3,4,5-trimethoxyphenethylamine-based BMND06. The...

Read more

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

July 17, 2024 9:00 AM

Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that it has successfully enrolled 50% of patients in its pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) study of DMT310, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. The STAR-1...

Read more

Briefly Bio Launches with $1.2m Funding to Help Scientists Reproduce Complex Experiments

July 17, 2024 8:30 AM

LONDON, UK / ACCESSWIRE / July 17, 2024 / Science is in a reproducibility crisis. In preclinical research, it's estimated that over 50% of efforts to reproduce experiments fail, costing the industry over $50bn each year. Solving this problem, techbio startup Briefly Bio has launched with software that makes lab work more reproducible by helping scientists capture and share their work clearly and consistently. With this launch, Briefly Bio has...

Read more

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

July 17, 2024 8:30 AM

BRIDGEWATER, NJ / ACCESSWIRE / July 17, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces the appointment of David H. Clarke as a Strategic Advisor to the Company's executive management team. "Tharimmune is pleased to have David join in an advisory capacity," stated Randy Milby, CEO of Tharimmune....

Read more

AbTherx Appoints Pallavi Tawde, PhD, as Head of Preclinical R&D Strategy

July 17, 2024 6:00 AM

AbTherx, a biotechnology company with innovative technologies that enable and accelerate therapeutic antibody discovery and development, today announced the appointment of Pallavi Tawde, PhD, to the newly created position of Head of Preclinical R&D Strategy. Dr. Tawde will oversee AbTherx's expansion of antibody discovery efforts including the development of single B cell technologies for targeting cell surface proteins and preclinical...

Read more

BioInvent Announces New Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BI-1607 in Combination with KEYTRUDA (Pembrolizumab) and Ipilimumab

July 17, 2024 2:30 AM

LUND, SE / ACCESSWIRE / July 17, 2024 / BioInvent International (STO:BINV) Agreement to support expansion of BI-1607 program with new Phase 2 triplet combination study in metastatic melanoma The study will evaluate anti-FcγRIIB antibody BI-1607 with low-dose anti-CTLA-4, ipilimumab, plus KEYTRUDA® Phase 1 data previously demonstrated BI-1607 is safe and well tolerated and achieves full receptor occupancy during the treatment interval at several...

Read more

Elixirgen Scientific Launches Advanced hiPSC-Derived Disease Panel for Alzheimer’s Disease

July 16, 2024 1:00 PM

Maryland-based biotechnology leader, Elixirgen Scientific, Inc., launches Alzheimer's Disease Panel, strengthening their commitment to quality and innovation in disease research and drug discovery. BALTIMORE, MD / ACCESSWIRE / July 16, 2024 / Elixirgen Scientific, Inc., a biotechnology leader focused on advancing drug discovery and revolutionizing cell therapy through hiPSC technology, announced today the launch of its new Alzheimer's Disease...

Read more

Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance

July 16, 2024 9:00 AM

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, announces results of the first of a series of pivotal studies aimed at facilitating FDA-approved OTC access of STENDRA® (avanafil) for consumers. The pivotal self-selection study showed that consumers who used the Company's proprietary Web App Technology,...

Read more

Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104

July 16, 2024 8:30 AM

BRIDGEWATER, NJ / ACCESSWIRE / July 16, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology, announces the launch of its new website at www.tharimmune.com. This redesigned online platform provides patients, healthcare professionals and stakeholders with comprehensive information about Tharimmune's cutting-edge...

Read more

Announcement from Biovica International AB's Extra General Meeting

July 15, 2024 9:45 AM

UPPSALA, SWEDEN / ACCESSWIRE / July 15, 2024 / The extra general meeting of Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) ("Biovica" or the "Company") was held today on 15 July 2024 and the following resolutions were passed by the meeting. SHARE SAVINGS PROGRAM 2024/2027:1 FOR SENIOR EXECUTIVES AND KEY PERSONNEL WITHIN THE COMPANY AND THE GROUP IN SWEDEN AND DENMARK The extra general meeting resolved, in accordance with the board...

Read more

Moolec Signs an Offtake Agreement With Major Global CPG Company to Hit the US Market in 2025

July 15, 2024 6:00 AM

LUXEMBOURG / ACCESSWIRE / July 15, 2024 / Moolec Science SA (NASDAQ:MLEC) ("the Company"), a Molecular Farming ingredient company, announced today the signing of an offtake agreement with one of the largest global consumer packaged goods and pet food companies for the use of Moolec's patented science-based GLA Safflower Oil product, GLASO™ (the "Agreement"). This initial offtake agreement has a term of three years and establishes commercial...

Read more

Alligator Bioscience AB Reports Financial Results for H1 2024 and Q2 2024 and Provides a Business Update

July 11, 2024 2:20 AM

LUND, SWEDEN / ACCESSWIRE / July 11, 2024 / Alligator Bioscience (STO:ATORX) Substantial overall survival benefit and unprecedented Duration of Response reported in 18-month analysis from mitazalimab OPTIMIZE-1 Phase 2 study in 1st line pancreatic cancer Positive Phase 2 mitazalimab data published in The Lancet Oncology Johan Giléus appointed as new Chief Financial Officer Orion exercises development option in research collaboration and license...

Read more

Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor

July 10, 2024 8:30 AM

Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces the appointment of Jules Haimovitz as a Strategic Advisor to the Company's executive management team. "We are pleased to have Jules join Tharimmune in an advisory capacity," stated Randy Milby, CEO of Tharimmune. "We believe his extensive success in the...

Read more

Shining a Spotlight on IBS: Anatara Lifesciences Makes Strides in Phase II Trial during IBS Awareness Month

July 9, 2024 12:30 PM

April was IBS Awareness Month, dedicated to shedding light on a condition that affects millions worldwide. ADELAIDE, SOUTH AUSTRALIA / ACCESSWIRE / July 9, 2024 / In Australia alone, statistics reveal the profound impact of Irritable Bowel Syndrome (IBS) on individuals and the economy. With 1 in 7 Australians affected by IBS, predominantly females at a ratio of 2:1 to males , the condition exerts a significant toll. Notably, IBS costs the...

Read more

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

July 9, 2024 8:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that the Company will host a symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain on August 8, 2024 in Amsterdam, Netherlands. The Symposium entitled: ‘Severe...

Read more

Dr. Alexander Sundermann Joins Next Gen Diagnostics as Its Director of Infection Prevention Services

July 9, 2024 8:00 AM

WEST PALM BEACH, FL / ACCESSWIRE / July 9, 2024 / Next Gen Diagnostics announces that Dr. Alexander Sundermann of the University of Pittsburgh School of Public Health, Department of Epidemiology has joined NGD as its Director of Infection Prevention Services. The part-time position will enable Dr. Sundermann to continue his research on the use of whole genome sequencing (WGS) to detect and curtail transmission of infection. Along with Dr. Lee...

Read more

Core One Enters into Loan Agreement with Right Season Investments

July 8, 2024 7:15 PM

Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6, WKN: A3CSSU) (the "Company" or "Core One"), is pleased to announce that it has entered into a loan agreement (the "Loan Agreement") with Right Season Investments Corp. ("Right Season") dated June 28, 2024. Under the terms of the Loan Agreement, Right Season has advanced a loan of CDN$300,000 (the "Loan") to the Company. The Loan is repayable upon demand of Right Season and carries an...

Read more

Scailyte Strengthens Its Leadership

July 8, 2024 12:00 PM

Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Darrin Crisitello as member of the BoD BASEL, SWITZERLAND / ACCESSWIRE / July 8, 2024 / Scailyte, a pioneer in single-cell and AI-driven biomarker discovery, is proud to announce the addition of three new members to its leadership team and BoD as the company continues to grow its business and to expand its presence in North America. Scailyte has...

Read more

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor

July 8, 2024 6:30 AM

KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to immunotherapies KVA12123 is currently in a Phase 1/Phase 2 clinical study as a monotherapy and in combination with Merck's anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors To date, KVA12123 has demonstrated a favorable...

Read more